References
- Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med 2011;62:347–360.
- Tseng HH, Chang JG, Hwang YH, et al. Expression of hepcidin and other iron-regulatory genes in human hepatocellular carcinoma and its clinical implications. J Cancer Res Clin Oncol 2009;135:1413–1420.
- Kamai T, Tomosugi N, Abe H, et al. Increased serum hepcidin-25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma. BMC Cancer 2009;9:270–275.
- Sharma S, Nemeth E, Chen Y-H, et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res 2008;14:3262–3267.
- Maes K, Nemeth E, Roodman GD, et al. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood 2010;116:3635–3644.
- Hohaus S, Massini G, Giachelia M, et al. Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. J Clin Oncol 2010; 28:2538–2543.
- Cheng PP, Sun ZZ, Jiang F, et al. Hepcidin expression in patients with acute leukemia. Eur J Clin Invest 2012;42:517–525.
- Ciccarelli BT, Patterson CJ, Hunter ZR, et al. Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011;11:160–163.
- Tisi MC, Bozzoli V, Giachelia M, et al. Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin. Leuk Lymphoma 2014;55:270–275.
- Katsume A, Miyai T, Suzuki H, et al. Interleukin-6 over-expression cannot generate serious disorders in severe combined immunodeficiency mice. Clin Immunol Immunopathol 1997;82: 117–124.
- Kawabata H, Tomosugi N, Kanda J, et al. Anti-interleukin-6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease. Haematologica 2007;92:857–858.
- Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 1998;18:555–559.
- Wang CQ, Udupa KB, Lipschitz DA. Interferon-gamma exerts its negative regulatory effect primarily on the earliest stages of murine erythroid progenitor cell development. J Cell Physiol 1995;162: 134–138.
- Hershman DL, Buonon DL, Malin J, et al. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. J Natl Cancer Inst 2009;101:1633–1641.
- Fung E, Sugianto P, Hsu J, et al. High-throughput screening of small molecules identifies hepcidin antagonists. Mol Pharmacol 2013;83:681–690.